The Lymphoma Hub is delighted to present a visual abstract summarizing key data from a phase II trial (NCT03075696) investigating the safety and efficacy of fixed-duration glofitamab monotherapy following pretreatment with obinutuzumab in adult patients with relapsed/refractory diffuse large B-cell lymphoma.
Glofitamab, a CD20 and CD3 bispecific monoclonal antibody that binds to CD20 b-cells and CD3 T-cells, leads to the engagement and redirection of a patient’s existing T-cells to eliminate malignant B-cells. Obinutuzumab is an anti-CD20 monoclonal antibody used in this study to mitigate cytokine release syndrome. The Lymphoma Hub has previously published an article and an interview on the phase I part of this study.
Read more here: Source link